| Year |
Citation |
Score |
| 2019 |
Hu Y, Gaillard PJ, de Lange ECM, Hammarlund-Udenaes M. Targeted Brain Delivery of Methotrexate by Glutathione PEGylated Liposomes: How can the Formulation Make a Difference? European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 30951819 DOI: 10.1016/J.Ejpb.2019.04.004 |
0.488 |
|
| 2019 |
Himawan E, Ekström P, Buzgo M, Gaillard P, Stefánsson E, Marigo V, Loftsson T, Paquet-Durand F. Drug delivery to retinal photoreceptors. Drug Discovery Today. PMID 30877076 DOI: 10.1016/J.Drudis.2019.03.004 |
0.368 |
|
| 2018 |
Hu Y, Gaillard PJ, Rip J, de Lange EC, Hammarlund-Udenaes M. In Vivo Quantitative Understanding of PEGylated Liposome's Influence on Brain Delivery of Diphenhydramine. Molecular Pharmaceutics. PMID 30376346 DOI: 10.1021/Acs.Molpharmaceut.8B00611 |
0.517 |
|
| 2018 |
Vighi E, Trifunović D, Veiga-Crespo P, Rentsch A, Hoffmann D, Sahaboglu A, Strasser T, Kulkarni M, Bertolotti E, van den Heuvel A, Peters T, Reijerkerk A, Euler T, Ueffing M, Schwede F, ... ... Gaillard P, et al. Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration. Proceedings of the National Academy of Sciences of the United States of America. PMID 29531030 DOI: 10.1073/Pnas.1718792115 |
0.381 |
|
| 2018 |
Kanhai KMS, Zuiker RGJA, Stavrakaki I, Gladdines W, Gaillard PJ, Klaassen ES, Groeneveld GJ. Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. British Journal of Clinical Pharmacology. 84: 1020-1028. PMID 29385232 DOI: 10.1111/Bcp.13525 |
0.309 |
|
| 2017 |
Greenwood J, Hammarlund-Udenaes M, Jones HC, Stitt AW, Vandenbrouke RE, Romero IA, Campbell M, Fricker G, Brodin B, Manninga H, Gaillard PJ, Schwaninger M, Webster C, Wicher KB, Khrestchatisky M. Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017. Fluids and Barriers of the Cns. 14: 31. PMID 29110676 DOI: 10.1186/S12987-017-0079-9 |
0.386 |
|
| 2017 |
Hu Y, Rip J, Gaillard PJ, de Lange E, Hammarlund-Udenaes M. The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: A In Vivo Microdialysis Study. Journal of Pharmaceutical Sciences. PMID 28322936 DOI: 10.1016/J.Xphs.2017.03.009 |
0.46 |
|
| 2016 |
Maussang D, Rip J, van Kregten J, van den Heuvel A, van der Pol S, van der Boom B, Reijerkerk A, Chen L, de Boer M, Gaillard P, de Vries H. Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo. Drug Discovery Today. Technologies. 20: 59-69. PMID 27986226 DOI: 10.1016/J.Ddtec.2016.09.003 |
0.529 |
|
| 2016 |
Gaillard PJ. BBB crossing assessment and BBB crossing technologies in CNS Drug Discovery. Drug Discovery Today. Technologies. 20: 1-3. PMID 27986217 DOI: 10.1016/J.Ddtec.2016.11.002 |
0.349 |
|
| 2015 |
Lindqvist A, Rip J, van Kregten J, Gaillard PJ, Hammarlund-Udenaes M. In vivo Functional Evaluation of Increased Brain Delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes. Pharmaceutical Research. PMID 26275529 DOI: 10.1007/S11095-015-1774-3 |
0.4 |
|
| 2015 |
Rotman M, Welling MM, Bunschoten A, de Backer ME, Rip J, Nabuurs RJ, Gaillard PJ, van Buchem MA, van der Maarel SM, van der Weerd L. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. Journal of Controlled Release : Official Journal of the Controlled Release Society. 203: 40-50. PMID 25668771 DOI: 10.1016/J.Jconrel.2015.02.012 |
0.423 |
|
| 2015 |
Aftimos PG, Milojkovic-Kerklaan B, Diéras V, Altintas S, Anders C, Arnedos M, Gelderblom H, Soetekouw P, Gladdines W, Gaillard P, Sousa Cd, Jager A, Linde Mv, Awada A, Schellens J, et al. Abstract P6-16-04: Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-16-04 |
0.389 |
|
| 2014 |
Lee DH, Rötger C, Appeldoorn CC, Reijerkerk A, Gladdines W, Gaillard PJ, Linker RA. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 274: 96-101. PMID 25037177 DOI: 10.1016/J.Jneuroim.2014.06.025 |
0.33 |
|
| 2014 |
Evans MC, Gaillard PJ, de Boer M, Appeldoorn C, Dorland R, Sibson NR, Turner MR, Anthony DC, Stolp HB. CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. Acta Neuropathologica Communications. 2: 66. PMID 24923195 DOI: 10.1186/2051-5960-2-66 |
0.32 |
|
| 2014 |
Birngruber T, Raml R, Gladdines W, Gatschelhofer C, Gander E, Ghosh A, Kroath T, Gaillard PJ, Pieber TR, Sinner F. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study. Journal of Pharmaceutical Sciences. 103: 1945-8. PMID 24801480 DOI: 10.1002/jps.23994 |
0.423 |
|
| 2014 |
Reijerkerk A, Appeldoorn CC, Rip J, de Boer M, Gaillard PJ. Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation. Investigative Ophthalmology & Visual Science. 55: 2788-94. PMID 24692123 DOI: 10.1167/Iovs.13-13599 |
0.364 |
|
| 2014 |
Holtman L, van Vliet EA, Appeldoorn C, Gaillard PJ, de Boer M, Dorland R, Wadman WJ, Gorter JA. Glutathione pegylated liposomal methylprednisolone administration after the early phase of status epilepticus did not modify epileptogenesis in the rat. Epilepsy Research. 108: 396-404. PMID 24556423 DOI: 10.1016/J.Eplepsyres.2014.01.010 |
0.353 |
|
| 2014 |
Rip J, Chen L, Hartman R, van den Heuvel A, Reijerkerk A, van Kregten J, van der Boom B, Appeldoorn C, de Boer M, Maussang D, de Lange EC, Gaillard PJ. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. Journal of Drug Targeting. 22: 460-7. PMID 24524555 DOI: 10.3109/1061186X.2014.888070 |
0.5 |
|
| 2014 |
Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ, Windhorst B, van Dongen GA, de Vries HE, Maussang D, van Tellingen O. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). Plos One. 9: e82331. PMID 24416140 DOI: 10.1371/Journal.Pone.0082331 |
0.478 |
|
| 2014 |
Gaillard PJ, Kerklaan BM, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, Verheul H, Awada A, Schellens J, Brandsma D. Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct216 |
0.405 |
|
| 2014 |
Kerklaan BM, Jager A, Aftimos P, Dieras V, Altintas S, Anders C, Arnedos M, Gelderblom H, Soetekouw P, Gladdines W, Gaillard P, Sousa Cd, Awada A, Schellens J, Linde Mv, et al. Nt-23Phase 1/2A Study Of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) In Breast Cancer Patients With Brain Metastases (Bcbm) Or Recurrent High Grade Gliomas (Hgg) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou265.21 |
0.386 |
|
| 2013 |
de Boer M, Visser CC, Gaillard PJ. Upcycling drugs for brain-related diseases: a sustainable future for targeted drug delivery. Therapeutic Delivery. 4: 435-8. PMID 23557284 DOI: 10.4155/Tde.13.7 |
0.388 |
|
| 2013 |
Lindqvist A, Rip J, Gaillard PJ, Björkman S, Hammarlund-Udenaes M. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. Molecular Pharmaceutics. 10: 1533-41. PMID 22934681 DOI: 10.1021/Mp300272A |
0.389 |
|
| 2013 |
Gaillard PJ, Dorland R, Appeldoorn CC. Abstract 4342: 2B3-201, glutathione pegylated liposomal methylprednisolone, prevents chemotherapy-induced neuropathic pain. Cancer Research. 73: 4342-4342. DOI: 10.1158/1538-7445.Am2013-4342 |
0.306 |
|
| 2012 |
Gaillard PJ, Visser CC, Appeldoorn CC, Rip J. Targeted blood-to-brain drug delivery --10 key development criteria. Current Pharmaceutical Biotechnology. 13: 2328-39. PMID 23016639 DOI: 10.2174/138920112803341815 |
0.504 |
|
| 2012 |
Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, Kooij G, de Vries HE, Reijerkerk A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 164: 364-9. PMID 22732475 DOI: 10.1016/J.Jconrel.2012.06.022 |
0.452 |
|
| 2012 |
Wisniewska-Kruk J, Hoeben KA, Vogels IM, Gaillard PJ, Van Noorden CJ, Schlingemann RO, Klaassen I. A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. Experimental Eye Research. 96: 181-90. PMID 22200486 DOI: 10.1016/J.Exer.2011.12.003 |
0.323 |
|
| 2012 |
Gaillard PJ, Gladdines W, Appeldoorn CCM, Rip J, Boogerd WJ, Beijnen JH, Brandsma D, Tellingen Ov. Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer Cancer Research. 72: 5687-5687. DOI: 10.1158/1538-7445.Am2012-5687 |
0.411 |
|
| 2012 |
Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J. Enhanced brain drug delivery: Safely crossing the blood-brain barrier Drug Discovery Today: Technologies. 9: e155-e160. DOI: 10.1016/J.Ddtec.2011.12.002 |
0.517 |
|
| 2011 |
Höbel S, Appeldoorn CC, Gaillard PJ, Aigner A. Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma. Pharmaceuticals (Basel, Switzerland). 4: 1591-1606. PMID 27721338 DOI: 10.3390/Ph4121591 |
0.316 |
|
| 2011 |
Scarpa M, Zaccariotto E, D'Avanzo F, Weperen Wv, Rip J, Gaillard P, Tomanin R. First evidence of efficacy in brain following intravenous injections of Brain-Targeted Liposome-Enzyme in the MPS II mouse model Molecular Genetics and Metabolism. 102. DOI: 10.1016/J.Ymgme.2010.11.135 |
0.438 |
|
| 2010 |
Gaillard PJ. Crossing barriers from blood-to-brain and academia-to-industry. Therapeutic Delivery. 1: 495-500. PMID 22833962 DOI: 10.4155/tde.10.43 |
0.304 |
|
| 2010 |
Tellingen Ov, Brandsma D, Appeldoorn CCM, Manca MF, Rip J, Dorland R, Kregten JMRv, Boogerd WJ, Beijnen JH, Gaillard PJ. Abstract 5537: GSH-conjugation improves efficacy of Doxil against intracranial xenografts Cancer Research. 70: 5537-5537. DOI: 10.1158/1538-7445.Am10-5537 |
0.419 |
|
| 2008 |
Gaillard PJ, de Boer AG. 2B-Trans technology: targeted drug delivery across the blood-brain barrier. Methods in Molecular Biology (Clifton, N.J.). 437: 161-75. PMID 18369968 DOI: 10.1007/978-1-59745-210-6_8 |
0.499 |
|
| 2007 |
de Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain barrier. Clinical Pharmacokinetics. 46: 553-76. PMID 17596102 DOI: 10.2165/00003088-200746070-00002 |
0.519 |
|
| 2007 |
de Boer AG, Gaillard PJ. Drug targeting to the brain. Annual Review of Pharmacology and Toxicology. 47: 323-55. PMID 16961459 DOI: 10.1146/Annurev.Pharmtox.47.120505.105237 |
0.522 |
|
| 2007 |
Gaillard PJ, Visser CC, De Boer AG. Drug Delivery to the Brain by Internalizing Receptors at the Blood-Brain Barrier Blood-Brain Barriers: From Ontogeny to Artificial Interfaces. 2: 501-520. DOI: 10.1002/9783527611225.ch21 |
0.41 |
|
| 2006 |
Gaillard PJ, de Boer AG. A novel opportunity for targeted drug delivery to the brain. Journal of Controlled Release : Official Journal of the Controlled Release Society. 116: e60-2. PMID 17718973 DOI: 10.1016/J.Jconrel.2006.09.050 |
0.48 |
|
| 2006 |
de Boer AG, Gaillard PJ. Blood-brain barrier dysfunction and recovery. Journal of Neural Transmission (Vienna, Austria : 1996). 113: 455-62. PMID 16550324 DOI: 10.1007/S00702-005-0375-4 |
0.448 |
|
| 2005 |
Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opinion On Drug Delivery. 2: 299-309. PMID 16296755 DOI: 10.1517/17425247.2.2.299 |
0.362 |
|
| 2005 |
Visser CC, Stevanovi? S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M, Crommelin DJ, de Boer AG. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 25: 299-305. PMID 15911226 DOI: 10.1016/J.Ejps.2005.03.008 |
0.441 |
|
| 2005 |
De Boer AG, Gaillard PJ. In vivo methods to estimate drug transport to the brain across the blood-brain barrier Medicinal Chemistry Reviews - Online. 2: 127-131. DOI: 10.2174/1567203053586973 |
0.481 |
|
| 2005 |
Gaillard PJ, Brink A, de Boer AG. Diphtheria toxin receptor-targeted brain drug delivery International Congress Series. 1277: 185-198. DOI: 10.1016/j.ics.2005.02.022 |
0.366 |
|
| 2004 |
Visser CC, Stevanovi? S, Heleen Voorwinden L, Gaillard PJ, Crommelin DJ, Danhof M, De Boer AG. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. Journal of Drug Targeting. 12: 145-50. PMID 15203893 DOI: 10.1080/10611860410001701706 |
0.424 |
|
| 2004 |
De Boer AG, Visser CC, Gaillard PJ. Characteristics and functions of the blood-brain barrier | Eigenschappen en functies van de bloed-hersenbarrière: Elke barrière heeft zijn bres Pharmaceutisch Weekblad. 139: 948-953. |
0.322 |
|
| 2003 |
Gaillard PJ, de Boer AB, Breimer DD. Pharmacological investigations on lipopolysaccharide-induced permeability changes in the blood-brain barrier in vitro. Microvascular Research. 65: 24-31. PMID 12535868 DOI: 10.1016/S0026-2862(02)00009-2 |
0.433 |
|
| 2003 |
de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annual Review of Pharmacology and Toxicology. 43: 629-56. PMID 12415123 DOI: 10.1146/Annurev.Pharmtox.43.100901.140204 |
0.435 |
|
| 2002 |
De Boer AG, Gaillard PJ. In vitro models of the blood-brain barrier: When to use which? Current Medicinal Chemistry - Central Nervous System Agents. 2: 203-209. DOI: 10.2174/1568015023358012 |
0.339 |
|
| 2002 |
Kamphorst W, Boer AGd, Gaillard PJ. Brain Drug Targeting: The Future of Brain Drug Development. Pardridge W M. Cambridge University Press, 2001, £65.00. ISBN 0 521 80077 3 Journal of Clinical Pathology. 55: 158-158. DOI: 10.1136/Jcp.55.2.158-A |
0.461 |
|
| 2002 |
De Boer AG, Gaillard PJ. The blood-brain barrier and drug transport to the brain S.T.P. Pharma Sciences. 12: 229-234. |
0.41 |
|
| 2001 |
van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharmaceutical Research. 18: 587-92. PMID 11465412 DOI: 10.1023/A:1011016923346 |
0.395 |
|
| 2001 |
Gaillard PJ, van Der Meide PH, de Boer AG, Breimer DD. Glucocorticoid and type 1 interferon interactions at the blood-brain barrier: relevance for drug therapies for multiple sclerosis. Neuroreport. 12: 2189-93. PMID 11447332 DOI: 10.1097/00001756-200107200-00029 |
0.378 |
|
| 2001 |
Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 12: 215-22. PMID 11113640 DOI: 10.1016/S0928-0987(00)00123-8 |
0.407 |
|
| 2000 |
Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharmaceutical Research. 17: 1198-205. PMID 11145224 DOI: 10.1023/A:1026406528530 |
0.425 |
|
| 2000 |
Gaillard PJ, de Boer AG. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 12: 95-102. PMID 11102736 DOI: 10.1016/S0928-0987(00)00152-4 |
0.432 |
|
| 1999 |
de Boer AG, Gaillard PJ, Breimer DD. The transference of results between blood-brain barrier cell culture systems. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 8: 1-4. PMID 10072472 DOI: 10.1016/S0928-0987(99)00003-2 |
0.397 |
|
| 1997 |
De Boer AG, Gaillard PJ, De Lange ECM, Breimer DD. In-vitro and in-vivo methods to assess drug transport to the brain Proceedings of the Controlled Release Society. 215-216. |
0.363 |
|
| 1997 |
Gaillard PJ, De Boer AG, Breimer DD. Astrocytes protect the in vitro blood-brain barrier against endotoxin mediated breakdown, through a steroid mediated pathway Endothelium: Journal of Endothelial Cell Research. 5: 358-359. |
0.341 |
|
| 1996 |
Gaillard P, de Boer A, Breimer D. Blood-brain barrier permeability and stress; a study excitotoxic stress and vasogenic edema European Journal of Pharmaceutical Sciences. 4: S195. DOI: 10.1016/S0928-0987(97)86598-0 |
0.343 |
|
| Show low-probability matches. |